Eventos adversos en la terapia farmacológica de la enfermedad inflamatoria intestinal

Meyer, Lital; Simian, Daniela; Lubascher, Jaime; Acuña, R; Figueroa, Carmen; Guillermo, Silva; Brahm, J; Quera, Rodrigo

doi:10.4067/s0034-98872015000100001

Cited by 14 publications

(15 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Currently, IBD treatment primarily focuses on immunosuppressive therapies involving biologicals, corticosteroids and immunomodulators [ 6 , 7 , 8 ]. However, the side effects of these treatments limit their therapeutic potential [ 8 , 9 , 10 , 11 ]. Hence, there is an urgent need for pragmatic treatment options targeting the multifactorial recurrent inflammatory cascade to mitigate chronic intestinal inflammation.…”

Section: Introductionmentioning

confidence: 99%

Idebenone Protects against Spontaneous Chronic Murine Colitis by Alleviating Endoplasmic Reticulum Stress and Inflammatory Response

et al. 2020

View full text Add to dashboard Cite

Endoplasmic reticulum (ER) stress in intestinal secretory goblet cells has been linked to the development of ulcerative colitis (UC). Emerging evidence suggests that the short chain quinone drug idebenone displays anti-inflammatory activity in addition to its potent antioxidant and mitochondrial electron donor properties. This study evaluated the impact of idebenone in Winnie mice, that are characterized by spontaneous chronic intestinal inflammation and ER stress caused by a missense mutation in the mucin MUC2 gene. Idebenone (200 mg/kg) was orally administered daily to 5–6 weeks old Winnie mice over a period of 21 days. Idebenone treatment substantially improved body weight gain, disease activity index (DAI), colon length and histopathology score. Immunohistochemistry revealed increased expression of MUC2 protein in goblet cells, consistent with increased MUC2 mRNA levels. Furthermore, idebenone significantly reduced the expression of the ER stress markers C/EBP homologous protein (CHOP), activating transcription factor 6 (ATF6) and X-box binding protein-1 (XBP-1) at both mRNA and protein levels. Idebenone also effectively reduced pro-inflammatory cytokine levels in colonic explants. Taken together, these results indicate that idebenone could represent a potential therapeutic approach against human UC by its strong anti-inflammatory activity and its ability to reduce markers of ER stress.

show abstract

Section: Introductionmentioning

confidence: 99%

Idebenone Protects against Spontaneous Chronic Murine Colitis by Alleviating Endoplasmic Reticulum Stress and Inflammatory Response

et al. 2020

View full text Add to dashboard Cite

show abstract

“…It was found that there was considerable improvement in hair condition. On the other hand, a recent study 16 showed the development of AA in 5 out of 146 patients with IBD while they were receiving azathioprine. Our case may be the first to document the response of alopecia universalis to azathioprine in a patient with UC.…”

Section: Discussionmentioning

confidence: 95%

Alopecia Universalis Associated with Ulcerative Colitis and The Role of Azathioprine

Shohdy

Rashad

Elmeligui

2018

Middle East J Dig Dis

View full text Add to dashboard Cite

Skin manifestations can herald, co-exist, or follow the evolution of inflammatory bowel disease (IBD). We report a middle-aged man with recent onset alopecia universalis and a history of intermittent diarrheal attacks for 6 years. Colonscopy and biopsy sampling confirmed ulcerative colitis. Regrowth of hair was achieved by treating the patient with azathioprine and mesalamine. Clinicians have to be aware that a multitude of skin manifestations with history of diarrhea can be an extraintestinal manifestation of IBD such as ulcerative colitis and this warrants further investigation.

show abstract

“…The pathogenesis of IBD is not completely defined, but recently the spotlight is on microbiota-stimulated immunoreactivity and adipose tissue hormonal dysregulation (Kostic et al, 2014; Schaubeck and Haller, 2015). What is more important, the currently available treatment includes 5-aminosalicylates, steroids, biological therapy and surgical procedures—all aggressive and with significant side effects (George et al, 2015; Khanna and Feagan, 2015; Meyer et al, 2015). Thus, it is crucial to seek new agents that could influence the clinical course of IBD and alleviate or prevent exacerbations.…”

Section: Pufas In Inflammatory Bowel Diseasesmentioning

confidence: 99%

Polyunsaturated Fatty Acids and Their Derivatives: Therapeutic Value for Inflammatory, Functional Gastrointestinal Disorders, and Colorectal Cancer

2016

View full text Add to dashboard Cite

Polyunsaturated fatty acids (PUFAs) are bioactive lipids which modulate inflammation and immunity. They gained recognition in nutritional therapy and are recommended dietary supplements. There is a growing body of evidence suggesting the usefulness of PUFAs in active therapy of various gastrointestinal (GI) diseases. In this review we briefly cover the systematics of PUFAs and their metabolites, and elaborate on their possible use in inflammatory bowel disease (IBD), functional gastrointestinal disorders (FGIDs) with focus on irritable bowel syndrome (IBS), and colorectal cancer (CRC). Each section describes the latest findings from in vitro and in vivo studies, with reports of clinical interventions when available.

show abstract

Eventos adversos en la terapia farmacológica de la enfermedad inflamatoria intestinal

Abstract: Background: The purpose of inflammatory bowel disease (IBD) treatment is to achieve resolution of symptoms and remission of disease with a minimum of adverse events (AE (Rev Med Chile 2015; 143: 7-13)

Cited by 14 publications

References 27 publications

Idebenone Protects against Spontaneous Chronic Murine Colitis by Alleviating Endoplasmic Reticulum Stress and Inflammatory Response

Idebenone Protects against Spontaneous Chronic Murine Colitis by Alleviating Endoplasmic Reticulum Stress and Inflammatory Response

Alopecia Universalis Associated with Ulcerative Colitis and The Role of Azathioprine

Polyunsaturated Fatty Acids and Their Derivatives: Therapeutic Value for Inflammatory, Functional Gastrointestinal Disorders, and Colorectal Cancer

Contact Info

Product

Resources

About